ReviewInternational journal of molecular sciences2021
Neurological Complications of COVID-19: Underlying Mechanisms and Management.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Facial Nerve Palsy Amid the SARS-CoV-2 Pandemic: A Pooled Analysis.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-facialePooled it
- Multiple Brain Microabscesses and a Lung Abscess Caused byInfectious disease reports · 2026Article
- Neuropathic Symptoms and Persistent Pain After Hospitalization for COVID-19: An 8-Month Longitudinal Follow-Up Study.Healthcare (Basel, Switzerland) · 2026Article
- Long-term risk of incident dementia following documented COVID-19 among older adults with type 2 diabetes: a propensity score-matched cohort study.Frontiers in aging neuroscience · 2026Article
- Cerebrospinal Fluid Proteomic Profiling Reveals Proteins Associated with Neuroinflammatory Response in COVID-19 Patients.ACS omega · 2025Article
- NMDA receptor antagonists mitigate COVID-19-induced neuroinflammation and improve survival in a mouse model.Scientific reports · 2025Article
- Guillain-Barré syndrome (GBS) after severe/critical COVID-19 or COVID-19 vaccination.European journal of medical research · 2025Article
- Impact of underlying diseases and complications on COVID-19 mortality in South Korea: analysis of national health insurance service data.Archives of public health = Archives belges de sante publique · 2025Article
- Neuropsychiatric Burden of SARS-CoV-2: A Review of Its Physiopathology, Underlying Mechanisms, and Management Strategies.Viruses · 2024Review
- Interplay between Comorbidities and Long COVID: Challenges and Multidisciplinary Approaches.Biomolecules · 2024Review
- Review
- Lessons we learned during the past four challenging years in the COVID-19 era: pharmacotherapy, long COVID complications, and vaccine development.Virology journal · 2024Review
- Extracellular Vesicles: The Invisible Heroes and Villains of COVID-19 Central Neuropathology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- COVID-19 and the brain: understanding the pathogenesis and consequences of neurological damage.Molecular biology reports · 2024Review
- mFrontiers in cell and developmental biology · 2024Review
- Review
- Cerebral Vasomotor Reactivity in COVID-19: A Narrative Review.Life (Basel, Switzerland) · 2023Review
- Importance of Magnesium Status in COVID-19.Biology · 2023Review
- Immune-Mediated Necrotizing Myopathy With Concurrent Statin Use After Routine COVID-19 Inoculation: A Case Report.Cureus · 2023Article
- COVID-19-Associated Acute Psychotic Disorder-Longitudinal Case Report and Brief Review of Literature.Medicina (Kaunas, Lithuania) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a severe respiratory disease caused by the newly identified human coronavirus (HCoV) Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The virus was discovered in December 2019, and in March 2020, the disease was declared a global pandemic by the World Health Organization (WHO) due to a high number of cases. Although SARS-CoV-2 primarily affects the respiratory system, several studies have reported neurological complications in COVID-19 patients. Headache, dizziness, loss of taste and smell, encephalitis, encephalopathy, and cerebrovascular diseases are the most common neurological complications that are associated with COVID-19. In addition, seizures, neuromuscular junctions' disorders, and Guillain-Barré syndrome were reported as complications of COVID-19, as well as neurodegenerative and demyelinating disorders. However, the management of these conditions remains a challenge. In this review, we discuss the prevalence, pathogenesis, and mechanisms of these neurological sequelae that are secondary to SARS-CoV-2 infection. We aim to update neurologists and healthcare workers on the possible neurological complications associated with COVID-19 and the management of these disease conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.